Refine my results
Document type
Institution
Specific Collection
Language
- English (2)
Author
- Pinton, Sandra (2)
- Revandkar, Ajinkya (2)
- Toso, Alberto (2)
- Alajati, Abdullah (1)
- Alimonti, Andrea (1)
- Andrea Alimonti (1)
- Arribas, Alberto (1)
- Bertoni, Francesco (1)
- Catapano, Carlo V. (1)
- Chen, Jingjing (1)
- Civenni, Gianluca (1)
- Delaleu, Nicolas (1)
- Di Mitri, Diletta (1)
- Dimitrov, Mitko (1)
- D’Antuono, Rocco (1)
- Fraering, Patrick (1)
- Garcia-Escudero, Ramon (1)
- Gerber, Hermeto (1)
- Gnetti, Letizia (1)
- Grassi, Fabio (1)
- Guccini, Ilaria (1)
- Jarrossay, David (1)
- Kalathur, Madhuri (1)
- Losa, Marco (1)
- Marini, Camilla (1)
- Montani, Erica (1)
- Nepveu, Alain (1)
- Pandolfi, Pier Paolo (1)
- Pasquini, Emiliano (1)
- Perciato, Maria Luna (1) More Less
Keyword
- Cancer genetics (1)
- Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However (1)
- Prostate cancer (1)
- activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in Pten-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2 (1)
- in Pten-null senescent tumors (1)
- providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly (1)
- these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments. (1)
- this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein (1)
- treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in Pten-null tumors. Altogether (1)
- we report that (1)